LCB-71

N/A

Report date: 2025/01/06 15:50:38
First In Class

Base Information

Drug NameLCB-71
Drug Alias NameCS-5001LCB-71ABL-202ROR1-pPBD
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > β-glucuronide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1Wnt signalling pathway modulatorsDNA inhibitors
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1DNA
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSouth Korea +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLegochem Biosciences IncAbl Bio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuXi XDC Cayman IncLegochembioCstone Pharmaceuticals +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma, B-Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A